Dr. Daver on CAR T-Cell Therapy Approval in Pediatric ALL

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the approval of a chimeric antigen receptor (CAR) T-cell therapy in pediatric acute lymphoblastic leukemia.

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the approval of a chimeric antigen receptor (CAR) T-cell therapy in pediatric acute lymphoblastic leukemia (ALL).

Tisagenlecleucel (Kymriah) is for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse.

Daver says that he believes the success seen in this setting with CAR T-cell therapy will spread to adult and older populations, as well.

Related Content:

OncLive TVPediatric OncologyHematologic Oncology
Dr Saad on the Continued Investigation of Darolutamide Plus ADT in mHSPC
Dr Singhi on Identifying Care Gaps and Unmet Needs in Early-Stage Lung Cancer
Dr Wander on Limitations of First- and Later-Line Therapies in HR+ Breast Cancer